{"denoms":[{"counts":[{"groupId":"BG000","value":"8"}],"units":"Participants"}],"groups":[{"description":"Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\>\n\n\\> Carfilzomib: Given IV\\>\n\n\\> Daratumumab: Given IV\\>\n\n\\> Dexamethasone: Given PO\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> Selinexor: Given PO","id":"BG000","title":"Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.43","value":"64.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"3"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Lines of Therapy","unitOfMeasure":"Participants"}]}